The Central Hospital of Xiaogan, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Hubei, China.
The Central Hospital of Xiaogan, Jinzhou Medical University, Hubei, China.
Medicine (Baltimore). 2023 Feb 10;102(6):e32844. doi: 10.1097/MD.0000000000032844.
Eczematous eruption is an increasingly recognized form of drug-related eruption, typically reported in association with interleukin 17 (IL-17)A inhibitors. However, severe paradoxical eczematous eruption due to IL-17A inhibitors has been rarely reported. Herein, we reported a case of a man with severe psoriasis with erythematous scaly plaques on the scalp, trunk, and arms and legs after the administration of secukinumab was initiated.
We reported a case of a 20-year-old man with severe psoriasis with erythematous scaly plaques on the scalp, trunk, and arms and legs after the administration of secukinumab was initiated. A skin biopsy was performed. It revealed spongiotic dermatitis consistent with eczematous reaction. Direct and indirect immunofluorescence assays were negative.
He was diagnosed with eczematous eruption.
Discontinuation of secukinumab and administration of cyclosporine and prednisone were considered.
Significant improvement was observed, with no adverse events.
Our case shows that eczematous eruption can paradoxically occur in patients on IL-17A inhibitors and this report is expected to increase awareness of the rising number of cutaneous eruptions related to biological agents.
特应性皮炎样发疹是一种越来越被认识到的与药物相关的发疹形式，通常与白细胞介素 17（IL-17）A 抑制剂相关报告。然而，由于 IL-17A 抑制剂导致的严重矛盾性特应性皮炎样发疹很少被报道。在此，我们报告了一例男性患者，在开始使用司库奇尤单抗后，头皮、躯干和四肢出现红斑鳞屑性斑块，诊断为严重银屑病。
我们报告了一例 20 岁男性患者，在开始使用司库奇尤单抗后，头皮、躯干和四肢出现红斑鳞屑性斑块，诊断为严重银屑病。进行了皮肤活检。它显示了与特应性皮炎反应一致的海绵状皮炎。直接和间接免疫荧光检测均为阴性。
他被诊断为特应性皮炎样发疹。
考虑停用司库奇尤单抗并给予环孢素和泼尼松治疗。
观察到显著改善，无不良反应。
我们的病例表明，IL-17A 抑制剂治疗的患者会出现特应性皮炎样发疹，该报告有望提高对与生物制剂相关的皮肤发疹数量增加的认识。
